Brasileiro, AFonseca Oliveira, JPinheiro, SPaiva-Lopes, MJ2018-01-152018-01-152016-05Lupus. 2016 May;25(6):663-5.http://hdl.handle.net/10400.17/2847The therapeutic efficacy of high-dose intravenous immunoglobulin in systemic lupus erythematosus (SLE) patients is well established. However, side effects might limit its use and lead to the consideration of therapeutic alternatives, such as the subcutaneous formulation of immunoglobulin, which has been used in some patients with other autoimmune diseases. We report a case of SLE refractory to classical therapies. High-dose intravenous immunoglobulin was effective, but gave rise to significant side effects. The patient was successfully treated with subcutaneous human immunoglobulin, achieving and maintaining clinical and laboratory remission. A lower immunoglobulin dose was needed and no side effects were observed, compared to the intravenous administration. Subcutaneous immunoglobulin could be a better-tolerated and cost-saving therapeutic option for select SLE patients.engDose-Response Relationship, DrugFemaleHumansImmunoglobulinsImmunoglobulins, IntravenousImmunologic FactorsInjections, SubcutaneousLupus Erythematosus, SystemicMiddle AgedTreatment OutcomeHSAC DERHSAC MEDjournal article10.1177/0961203316630116